Inhibrx Biosciences reported updated interim results from its Phase 1/2 study of Ozekibart (INBRX-109) combined with FOLFIRI in heavily pretreated patients with locally advanced or metastatic, unresectable colorectal cancer. The update is clinically relevant and modestly positive for the company, but the article provides no specific efficacy or safety data in the excerpt, limiting immediate market impact.
Inhibrx Biosciences reported updated interim results from its Phase 1/2 study of Ozekibart (INBRX-109) combined with FOLFIRI in heavily pretreated patients with locally advanced or metastatic, unresectable colorectal cancer. The update is clinically relevant and modestly positive for the company, but the article provides no specific efficacy or safety data in the excerpt, limiting immediate market impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
